Stay updated on Pembrolizumab in MM Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in MM Residual Disease Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.8%
    Check dated 2025-07-03T12:30:45.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-19T03:34:38.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-11T20:29:31.000Z thumbnail image
  5. Check
    35 days ago
    No Change Detected
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-28T12:57:27.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T00:13:13.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    The page has undergone significant updates, including the removal of detailed descriptions of a clinical trial for MK-3475 in Multiple Myeloma, while retaining the drug's name and the revision number. The focus has shifted from specific trial details to a more general mention of the drug and its context.
    Difference
    63%
    Check dated 2025-04-22T18:12:06.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in MM Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.